|
|
|
|
Cholelithiasis (gallstones) among patients exposed to atazanavir, other PIs, and PI-free regimens
|
|
|
Reported by Jules Levin
ICAAC 2014 Sept 5-9 Wash DC
Ella Nkhoma, PhD1, Monica Kumar, MD2, Patricia Hines, BA3, Vidya Moorthy, MS4 1Global Pharmacovigilance and Epidemiology (GPVE), Bristol-Myers Squibb (BMS), Wallingford, CT, USA; 2GPVE, BMS, Hopewell, NJ, USA; 3Center for Observational Research and Data Sciences, BMS, Hopewell, NJ, USA; 4Mu Sigma, Northbrook, Illinois, Chicago, USA
|
|
|
|
|
|
|